Emerging therapies in mantle cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Mantle cell lymphoma (MCL) is a rare, aggressive B cell non-Hodgkin's lymphoma with variable clinical presentations.
• Current first-line treatments include intensive chemotherapy with stem cell transplant for eligible patients and less intensive regimens for others.
• Patients with MCL often experience relapse, necessitating novel therapeutic strategies.

Purpose of the Study:

• To provide a comprehensive review of current and emerging therapeutic approaches for Mantle cell lymphoma.
• To discuss the impact of novel agents, including targeted therapies and cellular therapies, on MCL treatment.
• To highlight ongoing studies and future perspectives in MCL management.

Main Methods:

• Review of existing literature and clinical trial data on MCL treatments.
• Analysis of recent advancements in targeted therapies (BTK and BCL2 inhibitors).
• Evaluation of cellular therapies, including CAR T cells and BiTe antibodies, in relapsed MCL.

Main Results:

• Targeted therapies like BTK and BCL2 inhibitors demonstrate durable responses in MCL.
• Cellular therapies show promise for relapsed MCL, particularly after BTK inhibitor failure.
• Optimal combination and sequencing of novel therapies remain under investigation.

Conclusions:

• The treatment landscape for MCL is rapidly changing with the advent of novel targeted and cellular therapies.
• Future research will focus on optimizing treatment strategies for both frontline and relapsed MCL.
• Emerging therapies are expected to significantly improve outcomes for MCL patients.